Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

49 clinical studies listed.

Filters:

Alzheimer s Disease

Tundra lists 49 Alzheimer s Disease clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07279740

Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat apathy in individuals with Alzheimer's disease or mixed AD/vascular dementia

Gender: All

Updated: 2026-11-20

1 state

Alzheimer s Disease
Alzheimer Dementia (AD)
Alzheimer Dementia
+3
RECRUITING

NCT07169630

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI. Objective: To test whether medical imaging using a new radiotracer (\[18F\]PF-06445974) can measure PDE4B in the brains of people with AD or MCI. Eligibility: People aged 50 years and older with AD or MCI. Healthy volunteers are also needed. Design: Participants will have up to 5 clinic visits with 3 imaging scans of the brain. They will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory. Participants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each. Participants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....

Gender: All

Ages: 50 Years - 100 Years

Updated: 2026-11-20

1 state

Alzheimer s Disease
Mild Cognitive Impairment
Healthy
ENROLLING BY INVITATION

NCT07191821

TSPO Modulation in AD

The aim of this study is to determine whether pharmacological modulation of TSPO (with XBD173, 90mg twice daily, orally, for 28 days) improves neurovascular coupling (NVC) in AD relative to placebo. The main questions it aims to answer are: Does pharmacological modulation of TSPO (with XBD173, 90mg twice daily, orally, for 28 days) improve neurovascular coupling (NVC) in people with AD compared to placebo? NVC will be defined as the change in hippocampal cerebral blood flow (CBF) that follows a memory task (ΔCBF(h)). Does pharmacological modulation of TSPO (with XBD173, 90mg twice daily, orally, for 28 days): Increase cerebral blood flow (CBF); Reduce blood brain barrier leak (rate and volume) determined by Gd enhanced DCE-MRI; Increase plasma Amyloid 40/42; Reduce soluble markers of endothelial cell activation(sVCAM1, sICAM1, PECAM1, E-selectin, vWF); Improve markers of peripheral endothelial cell function; Cerebrovascular reactivity in response to CO2 inhalation The first six participants will undergo a dose escalation phase. The first 3 participants will receive XBD173 (90mg, once daily, 28 days) and the subsequent 3 participants will receive XBD173 (90mg, twice daily, 28 days). This phase will be open label. Participants will have 1 safety visits and 2 assessment visits. Each Assessment visit will involve clinical tests, a blood test and an MRI scan. Participants in the Randomisation phase participants will be given either 90mg of XBD173, twice daily or a placebo (dummy drug) for 4 weeks, have 2 safety visits and 4 assessment visits. Each Assessment visit will involve clinical tests, a blood test and an MRI scan. Healthy Volunteers will be recruited and undergo a screening visit and MRI scan.

Gender: All

Ages: 18 Years - 90 Years

Updated: 2026-11-19

Alzheimer s Disease
NOT YET RECRUITING

NCT07947446

CHUCOLATE: Current Knowledge and Prevalence of LATE-NC in Geriatric Memory Clinics at a Memory Center in Lorraine

LATE syndrome (Limbic-predominant Age-related TDP-43 Encephalopathy) is a neurocognitive disorder associated with TDP-43 proteinopathy, whose clinical presentation-a hippocampal amnestic syndrome-is similar to that of Alzheimer's disease. There are no specific markers to differentiate between the two, other than the exclusion of Alzheimer's biomarkers (AB), a criterion limited by the possibility of comorbidity. In the era of anti-amyloid therapies, it is crucial to differentiate between them in order to appropriately offer these therapies to patients. The clinical diagnosis of LATE is therefore of great importance. A pattern specific to LATE has been described on PET-CT and may facilitate this diagnosis. To study the concordance between the PET-CT pattern and the clinical criteria for LATE, we will compare changes in MMSE scores over one year between patients classified as "LATE" or "AD" based on 18F-FDG PET-CT.

Gender: All

Updated: 2026-11-19

Alzheimer s Disease
TDP-43 Proteinopathies
MCI
RECRUITING

NCT07573982

Ultrasonic Debris Clearance to Promote Brain Resilience

This pilot study will evaluate the safety, tolerability, and feasibility of Ultrasonic Debris Clearance (UDC), a noninvasive low-intensity focused ultrasound intervention, in amyloid-positive adults who are asymptomatic but at risk for Alzheimer's disease, or who have mild cognitive impairment or mild dementia. The study is designed to test whether repeated UDC sessions can be delivered safely and feasibly in this population, while also exploring efficacy via biomarkers and clinical measures.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

1 state

Alzheimer s Disease
MCI With Increased Risk for Alzheimer Disease
COMPLETED

NCT07672977

Home-Based Closed-Loop Auditory Stimulation to Enhance Slow-Wave Activity in MCI Due to Alzheimer's Disease: A Proof-of-Concept Study

This proof-of-concept study explores whether long-term home-based closed-loop auditory stimulation during sleep enhances slow-wave activity (SWA) and yields preliminary efficacy signals in patients with amnestic mild cognitive impairment due to Alzheimer's disease (MCI-AD), confirmed by cerebrospinal fluid (CSF) biomarkers or positron emission tomography (PET). The intervention is self-administered at participants' homes over an initial treatment period of 3 months, followed by a 1-month off-treatment (washout) period. Participants may then enter an optional extension phase consisting of 3 additional months of treatment followed by a second 1-month washout period, for a total study duration of up to 8 months. Participants who complete the Nana-Lab Study (NCT07402590) may be invited to provide informed consent for screening and potential enrollment in this study. All enrolled participants receive nightly active treatment during intervention periods. This study does not include randomization or a sham control group.

Gender: All

Ages: 50 Years - 75 Years

Updated: 2026-11-13

1 state

MCI-AD, Early Stage Alzheimer's Disease
Alzheimer s Disease
Mild Cognitive Impairment (MCI) Amnestic
+2
RECRUITING

NCT07402356

VR Pupillometry in Cognitive Impairment

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to brain arousal systems relevant to cognitive dysfunction, including the locus coeruleus, which is affected early in Alzheimer's disease. Adults aged 18-80 years will be assigned to one of four cohorts (n=35 per cohort): i) Alzheimer's disease (supported by CSF biomarkers), ii) mild cognitive impairment (MCI) without Alzheimer's Disease, iii) depressive disorder with cognitive impairment, iv) healthy controls. Participants will undergo initial assessments at baseline and follow-up visits after 6, 12 and 18 months. At each visit, pupil responses and behavioral metrics are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Pupillometric and behavioral metrics will be compared across cohorts and related to routine neuropsychological measures (MoCA, CERAD) and available clinical biomarkers (CSF markers; blood biomarkers). The primary objective is to determine whether task-evoked pupil response profiles sensitively quantify cognitive impairment, differ between cohorts, and track change over time. The long-term goal is to validate an easy-to-use, outpatient-compatible assessment to support objective characterization and monitoring of cognitive disorders.

Gender: All

Ages: 18 Years - 80 Years

Updated: 2026-11-12

1 state

Alzheimer s Disease
Major Depressive Disorder (MDD)
Mild Cognitive Impairment
+1
NOT YET RECRUITING

NCT07917182

Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)

Population aging is transforming the epidemiological landscape of the Asia-Pacific region at an unprecedented pace. By 2050, more than one quarter of the region's population will be aged over 60, with 36.7% of countries projected to become" super-aged" societies. Within Hong Kong specifically, the age- and gender-adjusted prevalence rates of mild and major neurocognitive disorder (NCD) among adults aged 60 years or above have been estimated at 21.8% and 9.7%, respectively. The scale of this burden intensifies considerably within institutional care environments, where roughly seven in ten long-term care (LTC) residents have been identified as having major NCD. Recent local survey data also indicate that severe cognitive impairment affects up to 49.8% of residents aged above 85 years. Given current demographic trajectories, the number of individuals living with dementia in Hong Kong is projected to triple over the next two decades. These trends underscore an urgent, time-sensitive need for scalable, accurate, and population-appropriate tools for the early detection and prognostic stratification of cognitive impairment, tools that must be actionable at the point of care and deployable at population scale. This study aim to generate a large database of cognitive, neuroimaging, plasma biomarkers, lifestyle and psychological information of the subjects who suffered from neurocognitive disorders

Gender: All

Ages: 40 Years - Any

Updated: 2026-11-10

Alzheimer s Disease
Mild Cognitive Impairment (MCI)
RECRUITING

NCT07924657

Acoustic Stimulation During Sleep for Alzheimer's Disease

This summary focuses on the acoustic stimulation part of the study. The goal of this interventional study is to learn if acoustic stimulation during sleep works to improve cognitive function in patients with Alzheimer's disease. It will also learn about safety and feasibility. The main questions are: Does acoustic stimulation during NREM sleep improve cognitive function in patients with mild cognitive impairment due to Alzheimer's disease (AD-MCI)? How does acoustic stimulation compare with sham stimulation? Researchers will compare acoustic stimulation with sham stimulation. Participants will: Be assigned to the acoustic stimulation group (n=20) or the sham stimulation group (n=20). Receive a familiar, comfortable sound at the bedside during stable NREM sleep, or sham stimulation, with 30 seconds of stimulation every 1 minute, triggered upon entering NREM sleep, with no limit on the number of stimulations. Complete cognitive assessments and sleep EEG monitoring before and after the intervention. Be monitored for safety throughout the study. The study is sponsored by Xuanwu Hospital, Capital Medical University. It is funded by the National Natural Science Foundation of China Key International Cooperation Project (Grant No. 82220108009). The study period runs from ethics approval to December 2024. No other centers are participating. Participants will be 60-75 years old and recruited from the neurology wards of Xuanwu Hospital.

Gender: All

Ages: 60 Years - 75 Years

Updated: 2026-11-09

Alzheimer s Disease
RECRUITING

NCT07911878

Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)

The I-FACE project aims to develop and validate a battery to assess famous-face recognition in people with neurodegenerative diseases and stroke. It will examine face naming, familiarity, and semantic knowledge, establish norms for the Italian population, and test how well the measures identify recognition difficulties in patients with frontotemporal dementia, Alzheimer's disease, and stroke.

Gender: All

Ages: 40 Years - 85 Years

Updated: 2026-11-03

5 states

Stroke
Alzheimer s Disease
Frontotemporal Degeneration (FTD)
RECRUITING

NCT07764146

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Gender: All

Ages: 30 Years - 80 Years

Updated: 2026-10-29

1 state

Alzheimer s Disease
NOT YET RECRUITING

NCT07892651

MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)

The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including individuals with chronic medical conditions and healthy volunteers. The registry will collect standardized clinical and participant-reported data, along with biological samples, to support the investigation of disease patterns, health-related characteristics, and population-specific biological and immunological profiles in populations historically underrepresented in biomedical research. The resulting data and samples may support future research into disease-associated biomarkers and underlying biological mechanisms.

Gender: All

Updated: 2026-10-23

Antiphospholipid (aPL)-Positive
Rheumatic Arthritis
Celiac Disease
+13
RECRUITING

NCT07346183

CommunityRx-Dementia + Peer Navigation (CRxDpeer)

The CRxDpeer intervention, delivered by a trained peer navigator, in practice called a "peer mentor", includes three evidence-based components: (a) focused education about common social (e.g., food and housing insecurity) and caregiving (e.g., respite and end of life care) needs, (b) activation of personalized community resource information for social and caregiving needs through delivery of a resource list (HealtheRx) at the baseline encounter and coaching on how to communicate with service providers, coordinate services and manage social support (e.g., connect with their peer navigator, reach out to friends or relatives for support, identify support groups, etc.) and (c) ongoing navigation-focused support meant to boost the baseline intervention, including a series of proactive text messages over 12 months. During this time, the subject can respond to and communicate with the peer navigator for ongoing support.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-13

1 state

Alzheimer s Disease
Dementia
Caregiver
+13
NOT YET RECRUITING

NCT07459959

LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response

The goal of this clinical trial is to assess feasibility, safety, tolerability, and central nervous system target engagement of oral lithium orotate in adults with biomarker-confirmed early Alzheimer's disease. The main questions it aims to answer are: * Can participants be recruited, retained, and remain adherent (target ≥80%) over 9 weeks of treatment, and what is the frequency and severity of adverse events? * Does lithium orotate increase cerebrospinal fluid (CSF) lithium concentration from baseline to 9 weeks compared with placebo? Researchers will compare daily lithium orotate to matched placebo to see if lithium orotate demonstrates acceptable feasibility, safety, and tolerability and engages the central nervous system target (CSF lithium). Participants will: * Be randomized in a double-blind manner to receive lithium orotate or placebo for 9 weeks, with titration from week 1: 240 mg/day (10mg elemental lithium) to week 2: 480 mg/day (20mg elemental lithium) and week 3: 720 mg/day (30mg elemental lithium) if tolerated; dose reductions are permitted for side effects. * Attend study visits for safety monitoring, adherence support (caregiver pill logs/diaries), and review of concomitant medications and adverse events. * Provide blood samples and undergo lumbar punctures at baseline and post-treatment to measure CSF and serum lithium and Alzheimer's-related biomarkers; complete brief cognitive testing and neuropsychiatric symptom assessments.

Gender: All

Updated: 2026-10-07

Alzheimer s Disease
RECRUITING

NCT07667478

NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE

The goal of this clinical trial is to learn if repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, can improve short-term memory in people with early Alzheimer's disease (AD). The study will also evaluate the safety of this approach. The main questions it aims to answer are: * Does rTMS applied to the cerebellum improve short-term memory in people with early AD? * How does this stimulation affect brain activity and connectivity measured by MRI? Researchers will compare active rTMS to sham rTMS (a look-alike procedure that does not deliver brain stimulation) to see if rTMS works to improve memory. Participants will: * Complete a screening visit with medical and memory assessments * Be randomly assigned to receive either active rTMS or sham rTMS (neither participants nor researchers will know the assignment during treatment) * Receive 20 rTMS sessions over 4 weeks (about 20 to 30 minutes per session) * Undergo two MRI scans, one before and one after treatment * Complete memory and thinking tests and questionnaires at baseline, immediately after treatment, and at 3- and 6-month follow-up visits Participation in the study will last about 6 months. The rTMS is generally well tolerated. The most common side effects include mild headache and scalp discomfort during treatment, which are usually short-lasting. MRI is non-invasive and safe for most people. Study procedures will be reviewed to ensure participant safety. Participants may or may not benefit directly from this study. People who receive active rTMS may experience improvement in memory. This research may help improve understanding of memory function in AD and support development of new treatments.

Gender: All

Ages: 55 Years - 90 Years

Updated: 2026-10-01

1 state

Alzheimer s Disease
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Mild Dementia
NOT YET RECRUITING

NCT07847944

Neuroprotective Effects of Oleanolic Acid and Erythrodiol in Prodromal Alzheimer's Disease

Alzheimer's disease begins many years before memory problems become obvious. People in the early ("prodromal") stage have memory complaints but are still independent in daily life. At present there is no treatment that prevents this stage from progressing to dementia. Olive oil contains two natural compounds, oleanolic acid and erythrodiol. Earlier work by this research team suggests that these compounds may reduce inflammation and oxidative stress and may improve the way the body handles sugars and fats, processes that are also altered in Alzheimer's disease. This study will test whether consuming olive oils that contain these compounds delays the progression from prodromal Alzheimer's disease to dementia. A total of 120 adults aged 50 to 80 years with prodromal Alzheimer's disease will take part at three public hospitals in southern Spain. Participants will be assigned by chance to one of three groups and will consume 55 mL per day of one of three oils for 12 months: olive oil enriched with oleanolic acid, pomace olive oil (which naturally contains both compounds), or a standard commercial olive oil with very low levels of these compounds. Neither the participants nor the staff assessing them will know which oil each person is receiving. Participants will attend study visits at the start of the study and after 6 and 12 months. At these visits they will complete memory and thinking tests, a physical and nutritional assessment, and blood and urine tests.

Gender: All

Ages: 50 Years - 80 Years

Updated: 2026-09-29

Alzheimer s Disease
Prodromal Alzheimer's Disease
NOT YET RECRUITING

NCT07841808

Precuneus Mapping With Sinaptistim® (an Investigational TMS-EEG System) in Mild to Moderate AD Patients

Transcranial magnetic stimulation (TMS), electroencephalography (EEG), and combined TMS-EEG approaches have been used in human research to characterize cortical excitability and network-level neurophysiologic responses. The SinaptiStim System is an investigational integrated TMS-EEG platform designed to synchronize TMS delivery, EEG acquisition, and is intended to support standardized characterization of neurophysiologic responses and individualized mapping of stimulation parameters relevant to later therapeutic use. The rationale for this early single-site, non-treatment study is to obtain initial clinical evidence that the investigational device can be used safely and as intended in participants with mild to moderate Alzheimer's disease (AD), can acquire EEG data of sufficient quality for the planned application, and can be implemented operationally at the clinical site with appropriate training and usability prior to launch of a larger treatment trial. The study involves two visits, a screening visit with magnetic resonance imaging (MRI) followed by a TMS-EEG mapping visit. Participants who complete this study successfully may be invited to provide informed consent for screening and potential enrollment in a future treatment protocol. This study does not include randomization or a sham control group or therapeutic treatment.

Gender: All

Ages: 65 Years - 85 Years

Updated: 2026-09-25

Alzheimer s Disease
RECRUITING

NCT07262645

Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

This study is a multicenter, randomized, double-blind, sham-device-controlled clinical trial. A total of 320 patients with mild to moderate Alzheimer's disease (AD) are planned to be enrolled. Central stratified block randomization will be applied, with stratification based on disease severity (mild vs. moderate) and Aβ-PET subgroup center status (yes vs. no). Participants will be randomly assigned to either the treatment group or control group in a 1:1 ratio. After enrollment, participants will complete the treatment at home during a 52-week double-blind period. The treatment group will receive therapy using a near-infrared light therapy device, while the control group will use sham device. Both investigators and participants will remain blinded to treatment allocation throughout the double-blind period. Participants who complete the 52-week double-blind treatment period may choose to enter an open-label extension and receive an additional 26 weeks of active near-infrared light therapy.

Gender: All

Ages: 50 Years - 85 Years

Updated: 2026-09-22

9 states

Alzheimer s Disease
NOT YET RECRUITING

NCT07251647

Adaptation of the Mini-Mental State Examination (MMSE) for the Reunion Island Population

The Mini-Mental State Examination (MMSE) is the most widely used cognitive screening and monitoring test for neurocognitive disorders in current clinical practice. Its French version was published in 1998 by the GRECO group (MMSE-GRECO). However, some items of this French version are not adapted to local Reunionese particularities. The main objective is to propose and validate the psychometric properties of an adapted version of the MMSE, to the Reunionese culture (MMSE-RUN) in a healthy population and in a sick population (Alzheimer's Disease and Vascular Cognitive Disorder), and to compare its performance with the MMSE-GRECO.

Gender: All

Ages: 60 Years - 89 Years

Updated: 2026-09-11

Alzheimer s Disease
Vascular Cognitive Impairment
RECRUITING

NCT07306598

[18F]NIDF PET Imaging in Tau-related Diseases

In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents. This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F\]NIDF PET imaging. \[18F\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific/off-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F\]NIDF PET imaging in human subjects.

Gender: All

Ages: 18 Years - 90 Years

Updated: 2026-09-08

3 states

Neurodegenerative Disease
Alzheimer s Disease
Tauopathies
NOT YET RECRUITING

NCT07796308

Terazosin And Metabolic Engagement in Alzheimer's Disease

The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.

Gender: All

Ages: 50 Years - 80 Years

Updated: 2026-09-01

1 state

Alzheimer s Disease
RECRUITING

NCT07324161

Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease

This study is grounded in the regulatory mechanisms of the glymphatic system and applies repetitive transcranial magnetic stimulation (rTMS) to the treatment of Alzheimer's disease (AD). The clinical efficacy and safety of rTMS will be systematically evaluated. Furthermore, transcranial magnetic stimulation-evoked potentials (TMS-EEG) and functional near-infrared spectroscopy (fNIRS) will be employed to investigate, from the perspectives of synaptic plasticity and neurovascular coupling, the mechanisms by which rTMS influences glymphatic function. Collectively, this work aims to provide new insights into both the therapeutic effectiveness and the underlying mechanisms of rTMS in AD.

Gender: All

Ages: 50 Years - 90 Years

Updated: 2026-08-31

1 state

Alzheimer s Disease
RECRUITING

NCT07786116

The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions

Gut problems, such as constipation, can have an important impact on quality of life of people who have them, and have been associated with higher risk of developing neurological diseases such as Parkinson's or Alzheimer's disease. Recent studies suggest that gut problems may also have implications for the progression of these diseases, as constipation is a risk factor for faster Parkinson's and Alzheimer's progression. However, how constipation and brain diseases are linked is unknown. Previous research has suggested that gut changes may lead to inflammation, which could play a role in accelerating the progression of both movement and memory problems in Parkinson's and memory and thinking problems in people with cognitive impairment. Methane is a gas that is naturally produced by microorganisms in the gut. Levels of methane can be measured using a simple breath test. Higher methane levels in the breath are thought to be more common in people with Parkinson's disease (PwP) when compared to people without Parkinson's (healthy controls) and have been associated with gut symptoms, particularly constipation, as well as worse movement problems in PwP, although they are less understood in conditions that affect memory and thinking (like dementia or mild cognitive impairment). The investigators want to better understand the changes in the gut of PwP and people with cognitive impairment (e.g. mild cognitive impairment or dementia). They will compare breath methane levels in PwP, people with cognitive impairment, people with REM Sleep Behaviour Disorder (a sleep condition linked to a higher risk of developing Parkinson's) and healthy participants. Participants will be followed-up over time to assess how methane levels are linked to changes in the blood and the stools, gut function, and clinical symptoms. This study has 2 components: Component 1: observational study, where the study investigators will follow 200 participants over 2 visits, 18 months apart. The study will recruit 4 groups of people: 50 people with Parkinson's disease, 50 people at high risk of developing Parkinson's disease (people with REM Sleep behaviour disorder), 50 people with other conditions affecting cognition (e.g. dementia, mild cognitive impairment), and 50 healthy controls. Component 2: study with 15 people with Parkinson's, who produce high methane levels, to test whether a probiotic (Lactobacillus reuteri) affects how much methane is produced.

Gender: All

Ages: 55 Years - Any

Updated: 2026-08-25

1 state

PARKINSON DISEASE (Disorder)
Parkinson
Parkinson Disease
+19
COMPLETED

NCT07279714

Fisetin in Mild Alzheimer's Disease

This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.

Gender: All

Ages: 60 Years - Any

Updated: 2026-08-20

1 state

Alzheimer s Disease
Alzheimer Dementia
Alzheimer Dementia (AD)
+4